Ocugen has announced positive preliminary 12-month data from its phase 2 ArMaDa trial evaluating OCU410 (AAV5-RORA) for the ...
A PSU report compiling 2025 Point-in-Time count data in Oregon noted over 27,000 people experiencing homelessness, both ...
Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may ...
Preliminary data from the 2025/26 Festive Season Road Safety Campaign indicates a five percent reduction in both fatalities and crashes when compared to the same period last year.
The proportion of Black drivers being stopped for traffic violations has dropped: Blacks made up less than 20 percent of ...
The National Interest on MSN
Harnessing AI to Move from Threat-to-Threat Reduction
AI is lowering barriers to CBRN threats—but with coordinated public-private partnerships, the same technologies can become ...
Stoke Therapeutics advances TANGO ASO for Dravet, with Zorevunersen Phase 3 data showing seizure reduction and a delayed 2027 ...
Ocugen (OCGN) traded higher in the premarket on Thursday after the company said that OCU410, its gene therapy for an eye ...
San Francisco has seen a measurable reduction in racially biased traffic stops since the implementation of a policy ...
China's holdings of US treasuries fell to $682.6 billion in November, down $6.1 billion month-on-month, according to data ...
24/7 Wall St. on MSN
Dave Ramsey and Suze Orman Have Opposite Advice on Social Security. The Data Is Clear on Who is Right
There’s a reason it’s important to put a lot of thought into your Social Security filing decision. The age you sign up for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback